Patents by Inventor Sriram Naganathan

Sriram Naganathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190218182
    Abstract: The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 18, 2019
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy, Linh Nguyen
  • Publication number: 20190185447
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 20, 2019
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • Patent number: 10273211
    Abstract: The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: April 30, 2019
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy, Linh Nguyen
  • Patent number: 10239858
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 26, 2019
    Assignees: EXELIXIS, INC., GENENTECH, INC.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • Publication number: 20190076420
    Abstract: The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 14, 2019
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy
  • Patent number: 10159666
    Abstract: The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 25, 2018
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy
  • Publication number: 20180230100
    Abstract: A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH or N; comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 16, 2018
    Inventors: Jo Ann Wilson, Sriram Naganathan, Neil G. Andersen, Matthew Pfeiffer
  • Patent number: 9969692
    Abstract: A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH or N; comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: May 15, 2018
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Sriram Naganathan, Neil G. Andersen, Matthew Pfeiffer
  • Publication number: 20170349569
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Inventors: SRIRAM NAGANATHAN, NATHAN GUZ, MATTHEW PFEIFFER, C. GREGORY SOWELL, TRACY BOSTICK, JASON YANG, AMIT SRIVASTAVA
  • Patent number: 9771347
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: September 26, 2017
    Assignee: Exelixis, Inc.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava
  • Publication number: 20170087143
    Abstract: The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
    Type: Application
    Filed: March 17, 2015
    Publication date: March 30, 2017
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy
  • Publication number: 20160229805
    Abstract: A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH or N; comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula 1.
    Type: Application
    Filed: April 20, 2016
    Publication date: August 11, 2016
    Inventors: Jo Ann Wilson, Sriram Naganathan, Neil G. Andersen, Matthew Pfeiffer
  • Patent number: 9365516
    Abstract: A process for preparing a compound of Formula I is disclosed: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH or N; comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 14, 2016
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Sriram Naganathan, Neil G. Andersen, Matthew Pfeiffer
  • Publication number: 20160031818
    Abstract: The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Inventors: Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy, Linh Nguyen
  • Publication number: 20150210668
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: SRIRAM NAGANATHAN, NATHAN GUZ, MATTHEW PFEIFFER, C. GREGORY SOWELL, TRACY BOSTICK, JASON YANG, AMIT SRIVASTAVA
  • Publication number: 20140256938
    Abstract: A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH or N; comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 11, 2014
    Inventors: Jo Ann Wilson, Sriram Naganathan, Neil G. Andersen, Matthew Pfeiffer
  • Publication number: 20130197230
    Abstract: Methods of preparing compounds of formula i(1): or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 join together with the nitrogen atom to which they are attached form a 6 membered heterocycloalkyl group; X1 is H, Br, Cl or F; X2 is H, Br, Cl or F; s is 2-6; n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: November 13, 2009
    Publication date: August 1, 2013
    Inventors: Jo Ann Wilson, Sharique Zuberi, Sriram Naganathan, Erick Goldman, James Kanter
  • Patent number: 8426415
    Abstract: Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: April 23, 2013
    Assignee: Symphony Evolution, Inc.
    Inventors: Sriram Naganathan, JoAnn Wilson, Daniel A. Dickman
  • Publication number: 20110003812
    Abstract: Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.
    Type: Application
    Filed: October 15, 2008
    Publication date: January 6, 2011
    Applicant: SYMPHONY EVOLUTION, INC.
    Inventors: Sriram Naganathan, JoAnn Wilson, Daniel Dickman